Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement

Leukemia

Volumn 17, Issue 6, 2003, Pages 1130-1136

  Viehmann, S ^a   Teigler Schlegel, A ^a   Bruch, J ^a   Langebrake, C ^b   Reinhardt, D ^b   Harbott, J ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

AML; AML1 ETO; Childhood; Minimal residual disease; Real time quantitative RT PCR

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; PREDNISONE; TIOGUANINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETO; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM METASTASIS; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE CONTROL; HUMAN; HUMAN CELL; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

EID: 0037702854     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402959     Document Type: Article

References (42)

1. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80: 1825-1831.
2. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12: 2715-2721.
3. Wolford JK, Prochazka M. Structure and expression of the human MTG8/ETO gene. Gene 1998; 212: 103-109.
4. Tighe JE, Daga A, Calabi F. Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia. Blood 1993; 81: 592-596.
5. Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993; 82: 1270-1276.
6. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
7. Saunders MJ, Tobal K, Keeney S, Liu YJ. Expression of diverse AML1/MTG8 transcripts is a consistent feature in acute myeloid leukemia with t(8;21) irrespective of disease phase. Leukemia 1996; 10: 1139-1142.
8. van de Locht LT, Smetsers TF, Wittebol S, Raymakers RA, Mensink EJ. Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia. Leukemia 1994; 8: 1780-1784.
9. Tighe JE, Calabi F. Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2. Blood 1994; 84: 2115-2121.
10. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
11. Gallego M, Carroll AJ, Gad GS, Pappo A, Head D, Behm F et al. Variant t(8;21) rearrangements in acute myeloblastic leukemia of childhood. Cancer Genet Cytogenet 1994; 75: 139-144.
12. Andrieu V, Radford-Weiss I, Troussard X, Chane C, Valensi F, Guesnu M et al. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol 1996; 92: 855-865.
13. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88: 2183-2191.
14. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735-739.
15. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712-715.
16. Sakata N, Okamura T, Inoue M, Yumura-Yagi K, Hara J, Tawa A et al. Rapid disappearance of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia following bone marrow transplantation and chemotherapy. Leukemia Lymphoma 1997; 26: 141-152.
17. Satake N, Maseki N, Kozu T, Sakashita A, Kobayashi H, Sakurai M et al. Disappearance of AML1-MTG8 (ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br J Haematol 1995; 91: 892-898.
18. Preudhomme C, Philippe N, Macintyre E, Henic N, Lai JL, Jouet JP et al. Persistence of AML1/ETO fusion mRNA in t(8;21) acute myeloid leukemia (AML) in prolonged remission: is there a consensus? [letter]. Leukemia 1996; 10: 186-188.
19. Morschhauser F, Cayuela JM, Martini S, Baruchel A, Rousselot P, Socie G et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol 2000; 18: 788-794.
20. Muto A, Mori S, Matsushita H, Awaya N, Ueno H, Takayama N et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95: 85-94.
21. Tobal K, Newton J, Macheta M, Chang J, Morgenstem G, Evans PA et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95: 815-819.
22. Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 1996; 88: 3704-3709.
23. Wattjes MP, Krauter J, Nagel S, Heidenreich O, Ganser A, Heil G. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia 2000; 14: 329-335.
24. Kondo M, Kudo K, Kimura H, Inaba J, Kato K, Kojima S et al. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia. Leukemia Res 2000; 24: 951-956.
25. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001; 19: 2705-2713.
26. Maruyama F, Stass SA, Estey EH, Cork A, Hirano M, Ino T et al. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 1994; 8: 40-45.
27. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van RF et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
28. Beillard E, Pallisgaard N, Bi W, van der Velden V, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and MRD detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - A Europe Against Cancer Program. Leukemia (in press).
29. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
30. Drexler HG, Dirks W, MacLeod RAF, Quentmeier H, Steube K, Uphoff CC. Human and animal cell lines. DSMZ Cat 1997, 6th edn, pp 75-84.
31. Gabert J, Beillard E, van der Velden V, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia (in press).
32. Lion T. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood 1999; 94: 1486-1488.
33. Sugimoto T, Das H, Imoto S, Murayama T, Gomyo H, Chakraborty S et al. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR. Am J Hematol 2000; 64: 101-106.
34. Fujimaki S, Funato T, Harigae H, Imaizumi M, Suzuki H, Kaneko Y et al. A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood. Eur J Haematol 2000; 64: 252-258.
35. Krauter J, Wattjes MP, Nagel S, Heidenreich O, Krug U, Kafert S et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol 1999; 107: 80-85.
36. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998; 12: 1482-1489.
37. Barragan E, Bolufer P, Moreno I, Martin G, Nomdedeu J, Brunet S et al. Quantitative detection of AML1 - ETO rearrangement by real-time RT-PCR using fluorescently labeled probes. Leukemia Lymphoma 2001; 42: 747-756.
38. Krauter J, Heil G, Ganser A. The AML1/MTG8 fusion transcript in t(8;21) positive AML and its implication for the detection of minimal residual disease. Hematol 2001; 5: 369-381.
39. Krauter J, Hoellge W, Wattjes MP, Nagel S, Heidenreich O, Bunjes D et al. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer 2001; 30: 342-348.
40. Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999; 26: 355-365.
41. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH 11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176-1181.
42. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443-449.